Reduced-intensity conditioning regimen may be option for allogeneic stem cell transplant in patients with ALL

December 2010
Hem/Onc Today;12/25/2010, Vol. 11 Issue 24, p16
The article reports on the potential of reduced-intensity conditioning regimen for the treatment of allogenic stem cell transplant in patients with acute lymphoblastic leukemia.


Related Articles

  • Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Arnold, R; Massenkeil, G; Bornhäuser, M; Ehninger, G; Beelen, D W; Fauser, A A; Hegenbart, U; Hertenstein, B; Ho, A D; Knauf, W; Kolb, H J; Kolbe, K; Sayer, H G; Schwerdtfeger, R; Wandt, H; Hoelzer, D // Leukemia (08876924);Dec2002, Vol. 16 Issue 12, p2423 

    The feasibility of nonmyeloablative stem cell transplantation (NST) was evaluated in 22 adults with high-risk ALL. 16/22 patients had advanced disease and 11/22 had Ph+ ALL. Eleven patients received NST as first stem cell transplantation (SCT). Eleven patients had relapses after allogeneic or...

  • Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL. Eefting, M; Halkes, C J M; de Wreede, L C; van Pelt, C M; Kersting, S; Marijt, E W A; von dem Borne, P A; Willemze, R; Veelken, H; Falkenburg, J H F // Bone Marrow Transplantation;Feb2014, Vol. 49 Issue 2, p320 

    A correction to the article regarding the treatment of acute lymphoblastic leukemia (ALL) in adult through myeloablative T cell-depleted allostem cell transplantation (SCT) with early sequential prophylactic donor lymphocyte infusion that was published in the August 12, 2013 is presented.

  • Pediatric.  // Bone Marrow Transplantation;3/2/2002 Supplement, Vol. 29 Issue 5, pS47 

    Bone Marrow Transplantation (2001) 29, Suppl. 2, S47–S50. DOI: 10.1038/sj/bmt/1703453

  • Allogeneic HSCT improved outcomes for children with relapsed ALL.  // Hem/Onc Today;8/10/2013, Vol. 14 Issue 15, p20 

    The article discusses research in Germany on the benefit of allogeneic hematopoietic stem cell transplantation (HSCT) in improving the prognosis of patients with acute lymphoblastic leukemia (ALL), referencing a study by C. Eckert published in an issue of the "Journal of Clinical Oncology."

  • Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. KW Song // Annals of Oncology;Mar2007, Vol. 18 Issue 3, p535 

    Background: Controversy exists regarding the role of high-dose therapy followed by stem-cell transplant (SCT) in the treatment of T-cell lymphoblastic lymphoma (T-LBL). We conducted an intention-to-treat analysis of the strategy of SCT as definitive treatment of T-LBL.Patients and methods: From...

  • Maintenance therapy with dasatinib after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Teng, Chieh-Lin; Yu, Jui-Ting; Chen, Hung-Chieh; Hwang, Wen-Li // Annals of Hematology;Aug2013, Vol. 92 Issue 8, p1137 

    A letter to the editor is presented on the topic related to an application of the drug Dasatinib's maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome (Ph) combined with acute lymphoblastic leukemia (ALL).

  • BY THE NUMBERS.  // Hem/Onc Today;6/10/2014, Vol. 15 Issue 11, p1 

    Statistics are given on the improved results of hematopoietic stem cell transplantation (HSCT) on patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) given with pre-transplant imatinib based on overall survival (OS), relapse, and non-release mortality rates.

  • Imatinib prior to HSCT improved outcomes in Ph+ALL.  // Hem/Onc Today;6/10/2014, Vol. 15 Issue 11, p11 

    The article focuses on the positive results of pre-transplant imatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) subjected to allogeneic hematopoietic stem cell transplantation (HSCT).

  • New drugs in haematopoietic stem cell transplantation for paediatric acute lymphoblastic leukaemia. Balduzzi, Adriana; Di Maio, Lucia // Drugs & Cell Therapies in Hematology;2016, Issue 1, p31 

    Patients relapsing after transplantation are at dismal prognosis and are eligible for experimental approaches. In the last decade novel strategies have been investigated in the setting of post-transplant relapse. A second transplantation is offered, often from an haploidentical related donor,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics